AGILeBiotics BV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AGILeBiotics BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11130
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AGILeBiotics BV (AGILeBiotics) is a pharmaceutical company that focus on the discovery and development of new antibiotics to treat multi-drug resistant infections. The company’s patented synthetic method technology OxaSelect transforms the currently available antibiotics, which became less effective owing to bacterial resistance, into new antibiotic derivatives that surmount bacterial resistance to treat severe infections caused by multi-drug resistant (MDR) bacteria. It works in collaboration with The University Medical Center Groningen, The University Hospital Muenster, The Hopsital Olderburg, Integrex Research, and Syncom BV, to design and develop novel antibiotic candidates. AGILeBiotics is a spin-off of the University of Groningen. The company operates in the Netherlands. AGILeBiotics is headquartered in Groningen, the Netherlands.

AGILeBiotics BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AGILeBiotics Raises Funds through Pre-Seed Financing 10
Partnerships 11
AGILeBiotics Enters into Agreement with Syncom 11
Equity Offering 12
AGILeBiotics Spin-Off from University of Groningen 12
AGILeBiotics BV – Key Competitors 13
AGILeBiotics BV – Key Employees 14
AGILeBiotics BV – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Strategy And Business Planning 16
Apr 10, 2017: AGILeBiotics joins the Health-i-Care program 16
Corporate Communications 17
Jun 01, 2017: AGILeBiotics Appoints Dr. Maria Bastian as CSO 17
Government and Public Interest 18
Feb 01, 2017: AGILeBiotics receives the Take-off fase one grant from NWO 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
AGILeBiotics BV, Pharmaceuticals & Healthcare, Key Facts 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Deals By Therapy Area, 2012 to YTD 2018 8
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AGILeBiotics Raises Funds through Pre-Seed Financing 10
AGILeBiotics Enters into Agreement with Syncom 11
AGILeBiotics Spin-Off from University of Groningen 12
AGILeBiotics BV, Key Competitors 13
AGILeBiotics BV, Key Employees 14

List of Figures
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AGILeBiotics BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[AGILeBiotics BV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Zhejiang Geely Holding Group Co Ltd:企業のM&A・事業提携・投資動向
    Zhejiang Geely Holding Group Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Zhejiang Geely Holding Group Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Altor BioScience Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Altor BioScience Corp (Altor BioScience) is a biopharmaceutical company that develops immunotherapies for the treatment of cancer and viral infections. The company’s pipeline products include ALT-801, ALT-836, and ALT-803. Its technologies are soluble t-cell antigen receptor, inhibitor of MH …
  • Suncor Energy Inc (SU):石油・ガス:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Nexans SA (NEX)-エネルギー分野:企業M&A・提携分析
    Summary Nexans S.A. (Nexans) is a provider of cables and cabling solutions. The company offers copper and fiber-optic cables and cabling systems. It serves network operators, equipment and infrastructure manufacturers, and builders, installers and distributors in submarine and land, oil and gas, min …
  • Emerald Resources NL (EMR):石油・ガス:M&Aディール及び事業提携情報
    Summary Emerald Resources NL (Emerald) is an oil and gas company that carries out mineral exploration and development. The company carries out acquisition, exploration, development and produces oil and natural gas, and gold deposits. Its projects include Okavu Gold project, and Magoffin County proje …
  • BOC Hong Kong (Holdings) Ltd:戦略・SWOT・企業財務分析
    BOC Hong Kong (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary BOC Hong Kong (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Crown Van Gelder N.V.:企業の戦略・SWOT・財務分析
    Crown Van Gelder N.V. - Strategy, SWOT and Corporate Finance Report Summary Crown Van Gelder N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Clementia Pharmaceuticals Inc (CMTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Clementia Pharmaceuticals Inc (Clementia) is a clinical stage biopharmaceutical company that focuses on the development of treatments for rare bone disorders and other diseases. Its lead product candidate Palovarotene is used for the treatment of fibrodysplasia ossificans progressiva (FOP), …
  • Clean Energy Fuels Corp (CLNE):企業の財務・戦略的SWOT分析
    Summary Clean Energy Fuels Corp (Clean Energy) is an oil and gas company that offers natural gas fuel transportation services. The company’s products fuels, liquefied natural gas, compressed natural gas, renewable natural gas, and bulk fuels. It also provides storage systems, compressors, dispensers …
  • Phosphagenics Ltd:企業のM&A・事業提携・投資動向
    Phosphagenics Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Phosphagenics Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Pierrel Spa (PRL)-製薬・医療分野:企業M&A・提携分析
    Summary Pierrel Spa (Pierrel) is a pharmaceutical company that offers contract services to biopharmaceutical and life sciences industries across the world. The company offers services in the areas of contract research, discovery of medicinal product candidates, clinical research and contract manufac …
  • Guardian Media Group plc:企業の戦略・SWOT・財務情報
    Guardian Media Group plc - Strategy, SWOT and Corporate Finance Report Summary Guardian Media Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Maxim Power Corp. (MXG):電力:M&Aディール及び事業提携情報
    Summary Maxim Power Corp. (Maxim) is an independent power producing corporation that acquires, develops, owns and operates power generation facilities and sells electricity and heat. The corporation generates electricity using various fuel sources including coal, natural gas, and wind, nuclear, hydr …
  • DSE, Inc.:企業の戦略・SWOT・財務情報
    DSE, Inc. - Strategy, SWOT and Corporate Finance Report Summary DSE, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Bank of Baroda:企業の戦略・SWOT・財務情報
    Bank of Baroda - Strategy, SWOT and Corporate Finance Report Summary Bank of Baroda - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Reynard Corp:企業の戦略・SWOT・財務分析
    Reynard Corp - Strategy, SWOT and Corporate Finance Report Summary Reynard Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Abdullah Al-Othaim Markets Co.:企業の戦略・SWOT・財務情報
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Olink Proteomics AB:企業の製品パイプライン分析
    Summary Olink Proteomics AB (Olink) is a biotechnology company that offers products and services for human protein biomarker research. The company provides portfolio of products such as biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. …
  • AmerisourceBergen Corporation:企業の戦略・SWOT・財務分析
    AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report Summary AmerisourceBergen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆